IOVA

Iovance Biotherapeutics Stock Analysis

AI Rating

Neutral
  • Quality2/10
  • Growth↑ 6/10
  • Value↓ 2/10
Iovance Biotherapeutics sales and earnings growth
IOVA Growth
Good
  • Revenue Y/Y↑ 6.88%
  • EPS Y/Y↑ 25.20%
  • FCF Y/Y↑ 12.22%
Iovance Biotherapeutics gross and profit margin trends
IOVA Profitability
Fair
  • Gross margin ↑ 36.70%
  • EPS margin↓ -123.90%
  • ROIC 5Y↓ -112.06%
Iovance Biotherapeutics net debt vs free cash flow
IOVA Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Iovance Biotherapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks